AnaptysBio(NASDAQ) ANAB

Current Price$55.02

Market Cap$1.63B

Since IPO (2017)+364%

5 Year+220%

1 Year+205%

1 Month-8%

AnaptysBio last closing stock price
Metric	Price	Date
Last close	USD 54.91	2026-07-23

AnaptysBio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+1.4%	USD 54.15	2026-07-16
1 month	-7.61%	USD 59.43	2026-06-23
3 month	-6.74%	USD 58.88	2026-04-24
Year to date	+69.92%	USD 32.32	2025-12-31
1 year	+205.1%	USD 18.00	2025-07-23
3 year	+365.67%	USD 11.79	2023-07-24
5 year	+219.91%	USD 17.16	2021-07-23
Since inception	+364.27%	USD 11.33	2017-01-26

AnaptysBio Financials at a Glance

Market Cap

$1.63B

Revenue (TTM)

$232.39M

Net Income (TTM)

-$26.79M

EPS (TTM)

-$1.08

P/E Ratio

-50.83

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$55.02

Volume

20,123

Open

$52.95

Price

$55.02

Volume

20,123

Open

$52.95

Previous Close

$55.02

Daily Range

$52.00 - $56.00

52-Week Range

$11.40 - $72.36

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$55.02

Volume

20,123

Open

$52.95

Previous Close

$55.02

Daily Range

$52.00 - $56.00

52-Week Range

$11.40 - $72.36

Estimated Earnings Date

Aug 5, 2026

ANAB News

What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally

Jonathan PoncianoJan 11, 2026

Page 1

ANAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AnaptysBio

AnaptysBio creates drugs for painful immune diseases. These treatments help patients with joint and skin issues. The company builds tools to stop harmful inflammation.

A Focused Drug Portfolio

Rosnilimab: Therapy for rheumatoid arthritis that removes specific T cells, which are immune cells that cause joint inflammation.
ANB033: Medicine for celiac disease, an immune reaction to gluten, that stops the body from attacking the gut.
ANB101: Drug designed to stop specific cells from releasing proteins that trigger autoimmune responses in the body.
Jemperli: Cancer medicine discovered by the company and sold by GSK to treat specific types of tumors.
Imsidolimab: Skin therapy licensed to Vanda Pharmaceuticals Inc. for treating rare and painful psoriasis flare-ups.

Strategic Steps Forward

Approved a plan in September 2025 to split into two independent, public companies to separate royalties from drug development.
Licensed imsidolimab to Vanda Pharmaceuticals Inc. in January 2025 for a $10 million upfront payment and future royalties.
Acquired global rights for the ANB101 program from Centessa Pharmaceuticals in November 2023.
Sold rights to future royalty payments to Sagard Healthcare Royalty Partners for $50 million in May 2024.

What Drives Success

AnaptysBio uses a specialized laboratory process to design antibodies that target specific biological triggers for disease. This precision allows the company to partner with global pharmaceutical giants while maintaining its own pipeline of experimental drugs.

Tracking the Numbers

Revenue reached $108.2 million in Q4 2025, a 151.1% increase from Q4 2024.
Net income hit $49.6 million in Q4 2025, up 327.8% from the previous year.
Operating cash flow grew to $98 million in Q4 2025, up 247% year-over-year.
Gross profit reached $216.2 million in Q4 2025, up 41166.6% from Q4 2024.
Market capitalization rose to $898.1 million in Q4 2025, up 234.1% from the previous year.

Evolution Summary

AnaptysBio has evolved from a discovery research firm into a clinical-stage developer with a focus on high-value immunology. Its strategy of licensing products to larger partners provides the capital needed to advance its internal drug candidates.

AI Generated • Apr 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Daniel R. Faga, MBA

Website

www.anaptysbio.com

Headquarters

San Diego, CA 92121-5801, US

ANAB Financials

Key Financial Metrics (TTM)

Gross Margin

116.42%

Operating Margin

17.56%

Net Income Margin

-11.53%

Return on Equity

442.91%

Return on Capital

93.32%

Return on Assets

-8.13%

Earnings Yield

-1.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.63B

Shares Outstanding

29.61M

Volume

20.12K

Avg. Volume

697.06K

Financials (TTM)

Gross Profit

$270.54M

Operating Income

$40.80M

EBITDA

$58.49M

Operating Cash Flow

$4.48M

Capital Expenditure

-$69.00K

Free Cash Flow

$4.41M

Cash & ST Invst.

$286.46M

Total Debt

$277.36M

AnaptysBio Performance Analysis

AnaptysBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 10,287,000	-83.7%
2023	2023-12-31	USD 17,157,000	66.8%
2024	2024-12-31	USD 91,280,000	432.0%
2025	2025-12-31	USD 234,603,000	157.0%

AnaptysBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-19.8%
Q3	2025-09-30	242.8%
Q4	2025-12-31	41.8%
Q1	2026-03-31	-76.4%

AnaptysBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.57	116.9%
2023	2023-12-31	USD -6.08	33.0%
2024	2024-12-31	USD -5.12	-15.8%
2025	2025-12-31	USD -0.46	-91.0%

AnaptysBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-4.7%
Q3	2025-09-30	138.8%
Q4	2025-12-31	203.8%
Q1	2026-03-31	-216.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$25.56M

-8.0%

Gross Profit

$24.95M

+286.0%

Gross Margin

97.61%

N/A

Market Cap

$1.63B

N/A

Market Cap/Employee

$15.63M

N/A

Employees

104

N/A

Net Income

-$52.88M

-34.5%

EBITDA

-$31.38M

-52.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$286.46M

-15.7%

Total Debt

$277.36M

+1680.8%

Accounts Receivable

$25.75M

+44.0%

Inventory

$0.00

N/A

Long Term Debt

$275.24M

+1921.9%

Short Term Debt

$2.12M

+8.1%

Return on Assets

-8.13%

N/A

Return on Invested Capital

14.17%

N/A

Free Cash Flow

-$25.94M

-141.6%

Operating Cash Flow

-$25.92M

-142.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TSHATaysha Gene Therapies, Inc.

TSHATaysha Gene Therapies, Inc.$5.83+3.00%

XNCRXencor, Inc.

XNCRXencor, Inc.$19.53+0.10%

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$23.74+0.59%

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$42.50+1.05%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$41.02-2.15%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$11.60-0.85%

BBOTBridgeBio Oncology Therapeutics Inc.

BBOTBridgeBio Oncology Therapeutics Inc.$8.72-2.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.76-0.29%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.56-0.08%

ONDSOndas

ONDSOndas$7.93-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$66.30-0.06%

SOFISoFi Technologies

SOFISoFi Technologies$16.65-0.02%

HBANHuntington Bancshares

HBANHuntington Bancshares$17.40-0.05%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$10.96+0.16%

Questions About ANAB

What is the current price of AnaptysBio?

AnaptysBio is trading at $55.02 per share.

What is the 52-week range for AnaptysBio?

Over the past 52 weeks, AnaptysBio has traded between $11.40 and $72.36.

How much debt does AnaptysBio have?

As of the most recent reporting period, AnaptysBio reported total debt of $277.36M.

How much cash does AnaptysBio have on hand?

AnaptysBio reported $248.47M in cash and cash equivalents in its most recent financial results.

What is AnaptysBio’s dividend yield?

AnaptysBio does not currently have a dividend yield.

AnaptysBio(NASDAQ) ANAB

AnaptysBio Financials at a Glance

ANAB News

What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally

What Investors Should Know About a $163K AnaptysBio Insider Sale

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

Why AnaptysBio Was Such a Healthy Stock This Week

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

Why AnaptysBio Stock Is Popping Today

Why AnaptysBio Shares Rose Nearly 14% on Thursday

Why AnaptysBio Plummeted Today

ANAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AnaptysBio

A Focused Drug Portfolio

Strategic Steps Forward

What Drives Success

Tracking the Numbers

Evolution Summary

ANAB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AnaptysBio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ANAB

What is the current price of AnaptysBio?

What is the 52-week range for AnaptysBio?

How much debt does AnaptysBio have?

How much cash does AnaptysBio have on hand?

What is AnaptysBio’s dividend yield?

Premium Investing Services